Literature DB >> 6869990

Prevalence of mycoplasmas and immune responses to Mycoplasma bovis in feedlot calves.

J T Boothby, D E Jasper, J G Zinkl, C B Thomas, J D Dellinger.   

Abstract

Microbiological cultural, cytologic, and immunologic observations were made on 30 calves. The eyes, nares, and bronchioalveolar region were subjected to microbiological cultural examination for mycoplasmas. Four of the examinations of 30 eyes, 15 of those of 30 nasal tissues, and 25 of those of the 30 bronchioalveolar regions from the 30 calves were positive for mycoplasmas. Mycoplasma bovis and M bovirhinis were the most prevalent species. Cytologic examinations of peripheral blood and bronchioalveolar washes did not show pathologic changes. Results of indirect hemagglutination, enzyme-linked immunosorbent assay, lymphocyte-stimulation tests on peripheral blood cells, and skin testing demonstrated only a low prevalence of immune recognition of M bovis. Infection and immune response were studied in 3 calves for 10 weeks before, and for 4 weeks after, intratracheal administration of live M bovis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6869990

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  10 in total

1.  In vitro infection of bovine monocytes with Mycoplasma bovis delays apoptosis and suppresses production of gamma interferon and tumor necrosis factor alpha but not interleukin-10.

Authors:  Musa Mulongo; Tracy Prysliak; Erin Scruten; Scott Napper; Jose Perez-Casal
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

2.  Experimental intramammary inoculation with Mycoplasma bovis in vaccinated and unvaccinated cows: effect on milk production and milk quality.

Authors:  J T Boothby; D E Jasper; C B Thomas
Journal:  Can J Vet Res       Date:  1986-04       Impact factor: 1.310

3.  Invasion of bovine peripheral blood mononuclear cells and erythrocytes by Mycoplasma bovis.

Authors:  Jacques van der Merwe; Tracy Prysliak; Jose Perez-Casal
Journal:  Infect Immun       Date:  2010-08-16       Impact factor: 3.441

4.  Immune responses to Mycoplasma bovis vaccination and experimental infection in the bovine mammary gland.

Authors:  J T Boothby; C E Schore; D E Jasper; B I Osburn; C B Thomas
Journal:  Can J Vet Res       Date:  1988-07       Impact factor: 1.310

5.  Coinfection with bovine viral diarrhea virus and Mycoplasma bovis in feedlot cattle with chronic pneumonia.

Authors:  Farshid M Shahriar; Edward G Clark; Eugene Janzen; Keith West; Gary Wobeser
Journal:  Can Vet J       Date:  2002-11       Impact factor: 1.008

6.  Experimental intramammary inoculation with Mycoplasma bovis in vaccinated and unvaccinated cows: effect on local and systemic antibody response.

Authors:  J T Boothby; D E Jasper; C B Thomas
Journal:  Can J Vet Res       Date:  1987-01       Impact factor: 1.310

7.  Changes in the bacterial flora of the upper and lower respiratory tracts and bronchoalveolar lavage differential cell counts in feedlot calves treated for respiratory diseases.

Authors:  J W Allen; L Viel; K G Bateman; S Rosendal
Journal:  Can J Vet Res       Date:  1992-07       Impact factor: 1.310

8.  Biological evaluation of Mycoplasma pulmonis temperature-sensitive mutants for use as possible rodent vaccines.

Authors:  W C Lai; M Bennett; Y S Lu; S P Pakes
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

9.  The association between serological evidence of mycoplasma infection and respiratory disease in feedlot calves.

Authors:  S Rosendal; S W Martin
Journal:  Can J Vet Res       Date:  1986-04       Impact factor: 1.310

10.  Mycoplasma bovis Infections in Free-Ranging Pronghorn, Wyoming, USA.

Authors:  Jennifer L Malmberg; Donal O'Toole; Terry Creekmore; Erika Peckham; Hally Killion; Madison Vance; Rebecca Ashley; Marguerite Johnson; Christopher Anderson; Marce Vasquez; Douglas Sandidge; Jim Mildenberger; Noah Hull; Dan Bradway; Todd Cornish; Karen B Register; Kerry S Sondgeroth
Journal:  Emerg Infect Dis       Date:  2020-12       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.